Abstract
Background: NAFLD has become one the most frequent liver disease in western countries. It is associated with Metabolic Syndrome, insulin resistance and diabetes. As well as the abovementioned conditions, it represents, a cardiovascular risk factor. Some evidences have demonstrated that Endothelial Dysfunction (ED),the pathophysiological basis of Cardiovascular Diseases (CVD),is present also in a part of NAFLD pts. ED can be evaluated in its “preclinical” status by performing vascular reactivity studies,such as Peripheral Artery Tonometry (PAT). However, not all NAFLD patients have a clinically demonstrable ED or a higher CVD risk. Untargeted Metabolomics is a novel and powerful method to discover biomarkers and give insights on diseases pathophysiology.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
